SEC Form 10-K filed by Lantern Pharma Inc.
$LTRN
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2022 | $34.00 → $36.00 | Buy | HC Wainwright & Co. |
| 11/2/2021 | $32.00 → $34.00 | Buy | HC Wainwright & Co. |
| 10/7/2021 | $32.00 | Buy | HC Wainwright & Co. |
4 - Lantern Pharma Inc. (0001763950) (Issuer)
4 - Lantern Pharma Inc. (0001763950) (Issuer)
4 - Lantern Pharma Inc. (0001763950) (Issuer)
HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $36.00 from $34.00 previously
HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $34.00 from $32.00 previously
HC Wainwright & Co. initiated coverage of Lantern Pharma with a rating of Buy and set a new price target of $32.00
Briefing to Feature a Live Walkthrough, Demonstration of Key Features, The Market Opportunity & Industry Need, Competitive Positioning, and Platform Monetization Strategy Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), an AI-driven clinical-stage precision oncology company, today announced it will host an investor, analyst and shareholder briefing on Thursday, April 9, 2026 at 8:30 AM Eastern featuring a live demonstration of withZeta.ai — the world's first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, and clinical trial design. The briefing will be conducted via live webcast and will cover the platform's capabilities and
Year of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization, and Global Trial Milestones LP-300 Phase 2 HARMONIC™ Trial Progress: Continued enrollment and patient follow-up across the United States, Japan, and Taiwan. Completion of targeted enrollment in Japan across five clinical sites including the National Cancer Center Tokyo. Preliminary data presented at the 66th Annual Meeting of the Japan Lung Cancer Society. Type C meeting package submitted to FDA in March 2026, with meeting scheduled for mid-May 2026 seeking feedback on proposed protocol amendments including focusing enrollment on EGFR exon 21 L858R patients and updating th
Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), an AI‑driven, clinical‑stage oncology company leveraging its proprietary RADR® platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third‑party website. The third‑party article incorrectly claimed that Panna Sharma has stepped down as President and Chief Executive Officer of Lantern. This claim is false, entirely without basis, and appears designed to mislead investors. No such communication has been issued by the Company or its Board of Directors. Mr. Sharma continues to serve as President, Chief Execu
SCHEDULE 13G - Lantern Pharma Inc. (0001763950) (Subject)
424B5 - Lantern Pharma Inc. (0001763950) (Filer)
10-K - Lantern Pharma Inc. (0001763950) (Filer)
Seasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member
DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manag
Year of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization, and Global Trial Milestones LP-300 Phase 2 HARMONIC™ Trial Progress: Continued enrollment and patient follow-up across the United States, Japan, and Taiwan. Completion of targeted enrollment in Japan across five clinical sites including the National Cancer Center Tokyo. Preliminary data presented at the 66th Annual Meeting of the Japan Lung Cancer Society. Type C meeting package submitted to FDA in March 2026, with meeting scheduled for mid-May 2026 seeking feedback on proposed protocol amendments including focusing enrollment on EGFR exon 21 L858R patients and updating th
Webcast to be held Monday, March 30th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2025 operating and financial results webcast on Monday, March 30, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2025 and provide guidan
Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch LP-184 Phase 1a clinical trial results demonstrate all primary endpoints achieved with 48% clinical benefit rate in evaluable cancer patients at or above therapeutic dose threshold; marked tumor reductions observed in patients with DNA damage repair mutations including CHK2, ATM, and STK11/KEAP1 alterations. FDA Type C meeting completed, providing regulatory guidance and pathway clarity for Starlight Therapeutics' planned pediatric CNS cancer trial in Atypical Teratoid Rhabdoid Tumor (ATRT) and confirming spironolactone combination strategy. LP-300 pr
SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)
SC 13G/A - Lantern Pharma Inc. (0001763950) (Subject)
SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)